Maximus (NYSE:MMS) Releases FY 2026 Earnings Guidance

Maximus (NYSE:MMS) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 8.050-8.350 for the period, compared to the consensus earnings per share estimate of 8.180. The company issued revenue guidance of $5.2 billion-$5.4 billion, compared to the consensus revenue estimate of $5.5 billion.

Maximus Stock Performance

NYSE:MMS opened at $75.17 on Friday. The company’s 50-day moving average price is $90.07 and its 200-day moving average price is $86.38. The company has a current ratio of 2.34, a quick ratio of 1.64 and a debt-to-equity ratio of 0.88. The company has a market cap of $4.10 billion, a P/E ratio of 11.44 and a beta of 0.57. Maximus has a twelve month low of $63.77 and a twelve month high of $100.00.

Maximus (NYSE:MMS) last announced its quarterly earnings data on Thursday, February 5th. The health services provider reported $1.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.84 by $0.01. Maximus had a net margin of 6.92% and a return on equity of 25.30%. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.37 billion. During the same quarter in the prior year, the company earned $1.61 EPS. Maximus’s revenue was down 4.1% compared to the same quarter last year. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. On average, sell-side analysts forecast that Maximus will post 6.15 earnings per share for the current fiscal year.

Maximus Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be given a dividend of $0.33 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Maximus’s previous quarterly dividend of $0.30. This represents a $1.32 dividend on an annualized basis and a yield of 1.8%. Maximus’s dividend payout ratio (DPR) is 21.58%.

Analysts Set New Price Targets

Several brokerages have issued reports on MMS. Zacks Research upgraded Maximus from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 30th. Weiss Ratings restated a “buy (b-)” rating on shares of Maximus in a research report on Monday, December 29th. Finally, Wall Street Zen lowered shares of Maximus from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to MarketBeat, Maximus has a consensus rating of “Strong Buy”.

Insider Buying and Selling at Maximus

In related news, insider Michelle F. Link sold 4,039 shares of Maximus stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $86.84, for a total value of $350,746.76. Following the completion of the sale, the insider owned 19,542 shares in the company, valued at approximately $1,697,027.28. This trade represents a 17.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.80% of the company’s stock.

Trending Headlines about Maximus

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Q1 EPS narrowly beat expectations — Maximus reported $1.85 EPS vs. the $1.84 consensus, showing earnings strength and year‑over‑year EPS improvement. Maximus (MMS) Q1 Earnings Top Estimates
• Positive Sentiment: Margins improved — management emphasized margin gains and cost discipline during the call, which supports near‑term profitability despite revenue pressure. Maximus Earnings Call: Margins Rise Amid Revenue Pressure
• Neutral Sentiment: Full disclosure and investor materials posted — the company released the press release, slide deck and earnings‑call transcript for detailed review (useful for modeling/QA but not market moving by itself). View Press Release / Slide Deck
• Negative Sentiment: Revenue miss and YoY decline — Q1 revenue was $1.35B vs. ~$1.37B expected and fell ~4.1% year‑over‑year, signaling near‑term top‑line weakness. Maximus Q1 results and materials
• Negative Sentiment: Tightened / lower FY‑2026 revenue guidance — management set FY‑2026 revenue of $5.2B–$5.4B (below Street ~ $5.5B) and EPS guidance of $8.05–$8.35 (around but slightly below consensus midpoint), which pressured growth expectations. Maximus tops Q1 earnings forecasts while tightening 2026 revenue guidance

Institutional Investors Weigh In On Maximus

Several institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada grew its position in Maximus by 146.2% in the 1st quarter. Royal Bank of Canada now owns 19,732 shares of the health services provider’s stock valued at $1,345,000 after acquiring an additional 11,716 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Maximus by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider’s stock valued at $2,351,000 after purchasing an additional 221 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Maximus by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 180,690 shares of the health services provider’s stock valued at $12,321,000 after purchasing an additional 11,754 shares in the last quarter. Jane Street Group LLC increased its stake in Maximus by 941.2% during the 1st quarter. Jane Street Group LLC now owns 98,273 shares of the health services provider’s stock worth $6,701,000 after buying an additional 88,835 shares during the period. Finally, Sivia Capital Partners LLC acquired a new stake in Maximus during the 2nd quarter worth approximately $204,000. Hedge funds and other institutional investors own 97.21% of the company’s stock.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.